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Does Timing of Adjuvant Chemotherapy for Early Breast
Cancer Influence Surv iva l?
By C. Shannon, S. Ashley, and I.E. Smith
Purpose: Theoretically, patients with early breast cancer
might benefit from starting adjuvant chemotherapy soon
after surgery, and this would have important clinical impli-
cations. We have addressed this question from a large,
single-center database in which the majority of patients
received anthracyclines.
Patients and Methods: A total of 1,161 patients from a
prospectively maintained database treated with adjuvant
chemotherapy for early breast cancer at the Royal Marsden
Hospital (London, United Kingdom), including 686 (59%)
receiving anthracyclines, were retrospectively analyzed.
The disease-free survival (DFS) and overall survival (OS) of
the 368 patients starting chemotherapy within 21 days of
surgery (group A) were compared with those of the 793
patients commencing chemotherapy > 21 days after
surgery (group B). Median follow-up time was 39 months
(range, 12 to 147 months).
Results: No significant difference in 5-year DFS was
found between the two groups overall (70% for group A v
72% for group B; P .4) or in any subgroup. Likewise, there
was no difference in 5-year OS (82% for group A v 84% for
group B; P  .2) or when the interval to the start of chemo-
therapy was considered as a continuous variable (P  .4).
Conclusion: We have been unable to identify any sig-
nificant survival benefit from starting adjuvant chemo-
therapy early after surgery, either overall or in any
subset of patients.
J Clin Oncol 21:3792-3797. © 2003 by American
Society of Clinical Oncology.
THE SURVIVAL benefit of adjuvant chemotherapy foroperable breast cancer is now firmly established,1 but its
optimal timing after surgery remains uncertain. Adjuvant che-
motherapy normally starts within a few weeks of surgery, but it
is unclear whether there is any gain from starting as soon as
possible or whether a delay has an adverse outcome.
There are theoretical reasons to believe that starting chemo-
therapy early might improve survival. First, in animal models, a
phase of accelerated growth of micrometastases after the re-
moval of the primary tumor has been demonstrated,2,3 along with
serum-transmissible growth factors responsible for accelerated
growth of tumor at distant sites.3,4 The administration of che-
motherapy or endocrine therapy preoperatively or in the periop-
erative period prevented this accelerated growth.5,6 Second, a
delay in the initiation of systemic therapy theoretically increases
the probability of the emergence of drug-resistant micrometa-
static disease.7 Third, there is evidence in animal models that the
removal of the primary tumor leads to an increase in angiogen-
esis in the vascular bed surrounding metastases,8 and it is
postulated that one of the mechanisms of action of chemotherapy
may be the inhibition of neoangiogenesis.
Two small clinical studies have suggested that patients who
received chemotherapy within 28 to 35 days of surgery had
improved disease-free survival (DFS) compared with those who
received chemotherapy later.9,10 More recently, a larger study
analyzed the effect of timing of cyclophosphamide, methotrex-
ate, and fluorouracil (CMF) chemotherapy on survival in pre-
menopausal patients participating in the International Breast
Cancer Study Group (IBCSG) trials I, II, and VI.11 This study found
a significant and clinically striking improvement in 10-year DFS in
a small subset of premenopausal patients with estrogen receptor
(ER)–absent tumors who started chemotherapy within 21 days of
surgery compared with those commencing chemotherapy 21 days
or more following surgery (60% v 34%; P  .0003). No similar
benefit was seen for other patients (the majority).
In the current era of anthracycline-based adjuvant chemother-
apy, we wished to investigate further whether there was a group
of patients for whom it was particularly important to start
treatment within the first 3 weeks after surgery. We have
therefore reviewed a single-center database of more than 1,000
patients, the majority of whom were treated with anthracycline-
based adjuvant chemotherapy.
PATIENTS AND METHODS
We identified retrospectively from a prospectively maintained database
1,161 patients treated with adjuvant chemotherapy for early breast carcinoma
between January 1990 and June 2001 at the Royal Marsden Hospital
(London, United Kingdom), either within clinical trials or on the basis of
standard service guidelines. Six hundred eighty-six of these patients received
anthracycline-based chemotherapy using combinations that mainly included
epirubicin 60 mg/m2 every 3 weeks for six courses (636 patients) or
sometimes doxorubicin 60 mg/m2 every 3 weeks for six courses (50
patients); the remaining 475 patients received CMF or mitoxantrone and
methotrexate (MM). Data were collected on known prognostic factors
including age, tumor size, grade, nodal status, number of involved lymph
nodes, lymphovascular invasion, and hormone receptor status. The time from
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surgery until the day of administration of the first cycle of adjuvant
chemotherapy was recorded. The date of surgery was taken as the date of the
first surgical excision of the primary tumor, whether or not a diagnostic
biopsy had preceded this date. Patients were divided into two groups with
respect to the initiation of adjuvant chemotherapy: those who received the
first dose of chemotherapy within 21 days of surgery (group A) and those
whose chemotherapy started 21 days or more after surgery (group B). Data on
radiotherapy and adjuvant endocrine therapy were also recorded. Data available
up to July 31, 2002, were used for this analysis. Median follow-up time was 39
months (range, 12 to 147 months).
Eighty-four percent of patients also received adjuvant endocrine therapy,
nearly always tamoxifen, given concurrently with the start of chemotherapy
for 5 years or in a trial comparing 2 years with 5 years of treatment.
All ER assays were conducted by a laboratory that participated in the
relevant UK National External Quality Assessment Scheme throughout this
period. Until 1992, ER was measured by multiple-point ligand-binding and
dextran-coated charcoal assay, with values obtained by Scatchard plot
analysis. Between 1993 and December 1994, ER was measured using
enzyme immunoassay kits (Abbott Diagnostics, Chicago, IL). In both of
these assays, values of 10 fmol/mg protein were considered positive. From
1995 onward, we used an immunocytochemical assay using the 1D5
antibody (DakoCytomation, Glostrup, Denmark). Results were calculated by
H score, in which the percentage of cells staining with intensities of 0, 1, 2,
or 3 were counted in 10 high-powered fields and summed to give a score,
which ranged from 0 to 300. Scores of  20 were considered positive; this
cutoff was formally established as being equivalent to an enzyme immuno-
assay concentration of  10 fmol/mg protein.12
Statistical Analysis
Baseline differences in pathologic variables between groups A and B were
assessed by means of the 2 test or Fisher’s exact test for categorical
variables and the Mann-Whitney nonparametric test for continuous variables.
Treatment imbalances were assessed by the 2 test or Fisher’s exact test.
DFS was defined as the date of first surgery (excluding diagnostic biopsy)
to the date of first relapse at any site or to the appearance of a second primary
breast cancer. Overall survival was measured from the date of first surgical
treatment to death from any cause or to last follow-up visit. Local recurrence
was defined as tumor arising in the treated breast, chest wall, or regional
lymph nodes. Survival curves were calculated using the Kaplan-Meier
method13 and differences assessed by the log-rank statistic.14 The Cox
proportional hazards regression model was used to test for the independent






On or After 21 Days
After Surgery
No. % No. %
Total no. of patients 368 793
Age, years
Median 48 48 .2
Range 18-68 22-75
Tumor size, cm
Median 2.0 cm 2.0 .9
Range 0-11 cm 0-12
Grade
1 21 5.7 32 4.0 .3
2 140 38.0 336 42.4
3 201 54.6 390 49.2
Not known 6 1.6 35 4.4
Lymphovascular invasion
Yes 204 55.4 403 50.8 .1
No 113 30.7 278 35.1
Not known 51 13.9 112 14.1
Estrogen receptor
Positive 188 51.1 480 60.5 .1
Negative 89 24.2 178 22.4
Unknown 91 24.7 135 17.0
Nodal status
Positive 241 65.5 487 61.4 .1
Negative 101 27.4 256 32.3
Unknown 26 7.1 50 6.3
No. of involved nodes
1-3 147 39.4 312 39.3 .1
4 or more 90 24.5 174 21.9
Treatment
Conservative surgery 306 83.2 605 76.3 .01
Mastectomy 62 16.8 188 23.7
Chemotherapy
Anthracycline*-based chemotherapy 205 55.7 481 60.7 .1
CMF or MM chemotherapy 163 44.3 312 39.3
Adjuvant endocrine treatment 318 86.4 656 82.7 .1
Local radiotherapy 281 76.4 565 71.2 .08
Abbreviations: CMF, cyclophosphamide, methotrexate, and fluorouracil; MM, mitoxantrone and methotrexate.
*Doxorubicin or epirubicin 60 mg/m2 every 3 weeks for six cycles.
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effect of timing of chemotherapy after adjusting for other prognostic and
treatment covariates.15 Covariates considered in the regression models
included pathologic tumor size, nodal status, grade, vascular invasion, ER
status, type of chemotherapy, and adjuvant endocrine therapy use. All
P values were two-sided.
RESULTS
Patient Characteristics
A total of 1,161 patients received adjuvant chemotherapy for
early breast cancer between January 1990 and June 2001. Of
these, 368 patients (31.7%) started chemotherapy within 21 days
of surgery (group A), and 793 patients started chemotherapy 21
days or more after surgery (group B). Of the 368 patients in
group A, 205 received anthracycline-based chemotherapy and
163 received either CMF or MM chemotherapy. Of the group B
patients, 481 received anthracycline-based chemotherapy and
312 received CMF or MM chemotherapy.
Table 1 lists the patients’ characteristics according to when
their chemotherapy began. Patient characteristics are well bal-
anced for age, tumor size, grade, incidence of lymphovascular
invasion, nodal status, number of involved nodes, and ER status.
The only significant difference between groups A and B is that
group A patients were more likely to have had conservative
breast surgery (P  .01).
DFS
There was no significant difference in DFS between patients
starting adjuvant chemotherapy within 21 days of surgery and
those commencing chemotherapy later (5-year DFS, 70% v 72%;
P  .4; Fig 1). Likewise, there were no significant differences in
DFS relating to age or ER status (Table 2). The Cox proportional
hazards model was used to adjust the analysis for known
prognostic factors of pathologic size, nodal status, number of
involved nodes, grade, vascular invasion, ER status, type of
chemotherapy, and use of adjuvant endocrine therapy. After
adjusting for these factors, the effect of the surgery-chemother-
apy interval remained nonsignificant (P  .5).
Overall Survival
There were no differences in overall survival between groups
A and B (5-year survival, 82% v 84%, respectively; P  .2; Fig
2). After adjustment for known prognostic factors, there re-
mained no difference in survival between the two groups (P 
.4). We were likewise unable to show that the timing of
Fig 1. Kaplan-Meier curve for disease-free survival according to days from
surgery to the start of adjuvant chemotherapy. dy, days.
Fig 2. Kaplan-Meier curve for overall survival according to days from surgery
to the start of adjuvant chemotherapy. dy, days.




Before 21 Days After Surgery On or After 21 Days After Surgery
n 5-Year DFS (%) n 5-Year DFS (%)
Total No. of patients 368 70 793 72 .4
Age  50 years 208 68 440 72 .3
ER negative 53 63 98 62 .6
ER positive 102 75 251 76 .6
Node positive 130 66 235 65 .9
Age  50 years 160 74 353 73 .9
Abbreviations: DFS, disease-free survival; ER, estrogen receptor.
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chemotherapy influenced survival significantly for subgroups
related to age or ER status (Table 3).
Continuous Variable Assessment
We also assessed whether any other time interval might
influence outcome. One-third of the total patient population had
their adjuvant chemotherapy initiated within 21 days of surgery,
but the majority (65%) started adjuvant chemotherapy between
day 14 and 35 after surgery (Fig 3). We found no effect of timing
of chemotherapy on survival when the interval is considered as a
continuous variable (P  .4). Likewise, we found no survival
difference using either a 28-day (P .1) or 35-day cutoff (P .3).
DISCUSSION
Despite the experimental data discussed above,3,8 which
indicate that starting adjuvant chemotherapy early might have a
survival benefit in early breast cancer, we have been unable to
demonstrate this clinically. In a patient population treated in a
single center during a 10-year period, we found no difference in
outcome relating to how soon chemotherapy was started after
surgery, either overall or in any subgroup of that population.
This was the case whether we used an arbitrary 21-day cutoff
point or assessed time as a continuous variable.
The largest previous study to address this question retrospec-
tively analyzed data from three IBCSG trials of adjuvant CMF
chemotherapy given to premenopausal, node-positive patients.11
In this analysis, there was heterogeneity in the duration and total
dose of chemotherapy received. A remarkable improvement in
10-year DFS (60% v 34%) was found for a small subgroup of
premenopausal patients with node-positive, ER-absent tumors
receiving CMF chemotherapy (226 of 1,788 patients [13%])
within 21 days of surgery compared with those starting treatment
later (hazard ratio [HR], 0.48; 95% CI, 0.33 to 0.72; P  .0003).
This far exceeds anything achieved by any specific form of
adjuvant therapy itself and would have important clinical impli-
cations for delivery of treatment if confirmed. No similar benefit
was seen for any other subgroup of patients.
It should be noted that patients who had received adjuvant
oophorectomy or other endocrine therapy were excluded from
the IBCSG study, whereas 84% of our patients also received
endocrine therapy (nearly always tamoxifen) given concurrently
with chemotherapy. It is possible that this had a confounding




Before 21 Days After Surgery On or After 21 Days After Surgery
n 5-Year OS, % n 5-Year OS, %
Total No. of patients 368 82 793 84 .2
Age  50 years 208 83 440 85 .3
ER negative 53 74 98 70 .9
ER positive 102 93 251 92 .6
Node positive 130 78 235 83 .4
Age  50 years 160 80 353 81 .3
Abbreviations: OS, overall survival; ER, estrogen receptor.
Fig 3. Interval from surgery to the start of
adjuvant chemotherapy.
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effect on the influence of chemotherapy. More importantly,
although our finding of no benefit from early chemotherapy
included premenopausal women with ER-negative cancers, we
nevertheless cannot make direct comparisons on this issue
between the IBCSG study and our own because of differences in
ER categorization. Throughout the period of our study, ER was
measured using a biochemical cutoff for positivity of  10
fmol/mg protein or an H score of  20, which was shown to
equate to a biochemical cutoff of  10 fmol/mg protein12 (see
Patients and Methods). In contrast to the IBCSG but in common
with most other centers, during the early 1990s, we did not create
additional semiquantitative categories, including ER-absent and
ER-low groups ( 1 and 1 to 9 fmol/mg protein), respectively,
for the ER-negative group. The IBCSG study did not report these
two groups combined as a single ER-negative category. Never-
theless, it seems likely from their data that if they had done so,
the significant effect noted in the ER-absent group would have
been lost as a result of combination with the more numerous
ER-low group of tumors in which no significant effect was seen.
In this respect, therefore, our two studies appear to have
consistent findings.
It should be noted, however, that diagnostic cutoffs for ER
have changed in many centers such that what are now described
as ER-negative tumors closely approximate the IBCSG descrip-
tion of ER-absent tumors. This is because of recent studies
showing a better prognosis for tumors with as few as 1% cells
staining positive when treated with tamoxifen.16 Thus the small
subgroup of ER-absent tumors is increasingly relevant to con-
temporary practice.
In other studies, Buzdar et al17 likewise did not find any
differences in DFS according to length of delay in initiation of
chemotherapy. In their study of 462 patients receiving adjuvant
fluorouracil, doxorubicin, and cyclophosphamide, overall 4-year
DFS was 64%, 68%, 60%, and 63% for patient groups with
delays of less than 10, 10 to 13, 14 to 17, or  18 weeks,
respectively. In this study, only 13% of patients started chemo-
therapy within 10 weeks of surgery. This study therefore
addressed the issue of long delays in the starting of adjuvant
chemotherapy but provided less information on the significance
of starting early in the postoperative period.
Pronzato et al10 showed improved DFS for patients starting
chemotherapy within 35 days of surgery. This study examined
small numbers of patients (n  229) receiving adjuvant intrave-
nous CMF, and survival was analyzed according to the number
of cycles received, dose-intensity, and time to start of chemo-
therapy. All three factors were significant in a univariate analy-
sis, but only dose-intensity and time to start of chemotherapy
retained independent prognostic significance in multivariate
analysis. Brooks et al9 also showed an improvement in DFS for
patients with node-positive cancers receiving doxorubicin and
cyclophosphamide chemotherapy within 4 weeks of surgery
compared with those patients receiving delayed chemotherapy,
but did not identify patient groups for whom the early chemo-
therapy was particularly important. In a retrospective Turkish
study involving 1,167 patients receiving adjuvant chemotherapy
between 1990 and 2000, it was found that time to start of
adjuvant chemotherapy and time to progression were inversely
related for patients receiving adjuvant chemotherapy within 4.8
months.18 No data were given on what type of chemotherapy
was used or whether there were specific subgroups who bene-
fited from starting early. In their multivariate analysis, time to
initiation of chemotherapy remained an independent prognostic
variable. None of these studies provided sufficient numbers
and/or demographic details to allow a premenopausal ER-absent
subgroup equivalent to that identified by the IBCSG to be
separately analyzed.
A trial of perioperative chemotherapy showed that patients
receiving one course of perioperative polychemotherapy had
significantly improved progression-free survival compared with
patients having surgery alone, but not in patients who received
additional conventional adjuvant chemotherapy subsequently.19
In this study, the timing effect of one course of perioperative
fluorouracil, doxorubicin, and cyclophosphamide was analyzed
in the 1,198 patients who received prolonged adjuvant systemic
treatment (chemotherapy or endocrine treatment). No effect of
timing was found on overall survival (HR, 0.65; 95% CI, 0.78 to
1.17; P  .65) or progression-free survival (HR, 0.94; 95% CI,
0.80 to 1.12; P .50). In addition, no effect of timing was found
on locoregional control (HR, 0.88; 95% CI, 0.59 to 1.31; P 
.52). This would suggest that total dose and duration of chemo-
therapy are more important than the timing of the start of
chemotherapy. This trial suggests that one course of periopera-
tive chemotherapy is better than no systemic therapy at all, but
does not show that the perioperative timing confers a survival
advantage superior to that of standard adjuvant therapy.
In conclusion, we have been unable to show any clinical
benefit from commencing chemotherapy (usually anthracycline-
based) early after surgery in any patient subgroup, including
those we defined in the past as having ER-negative cancers. The
issue remains unresolved, however, for the small subgroup with
ER-absent tumors defined biochemically. Currently, this would
approximate to immunohistochemically defined ER-negative
tumors in an increasing number of centers, depending on cutoff.
There are obvious practical and ethical difficulties in conducting
a prospective randomized trial to address this issue, and the best
way to proceed seems to be analysis of additional retrospective
studies from large, prospectively assembled databases.
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